Kornimate/medical-research-clean huggingface dataset:
pistachios, performance, metabolomics

Conditions: Inflammation; Oxidative Stress; Immune Dysfunction

Summary: ingestion of 3 ounces of pistachio nuts per day for two weeks before and the day of cycling intensely for 75 kilometers will support substrate utilization during exercise (as determined through metabolomics) and improve performance compared to water only, and attenuate inflammation, oxidative stress, and immune dysfunction during 24 hours of recovery.


Eligibility criteria:
inclusion criteria: * male endurance cyclists * capable of exercising for 2.5 h at a high intensity in the lab * ages 18-55 * agree to train normally and stay weight stable. * agree to avoid the use of large dose vitamin/mineral supplements * agree to avoid herbs and medications that influence inflammation exclusion criteria: * regularly take supplements or medicines known to effect inflammation. * at moderate or high risk for cardiovascular disease. * younger than 18 or older than 55 years of age. * no history of competing in cycling races.

Keywords: inflammation oxidative stress immune dysfunction metabolites
a study evaluating the safety and efficacy of the lentiglobin bb305 drug product in β-thalassemia major participants

Conditions: β-thalassemia Major

Summary: this is a non-randomized, open label, multi-site, single-dose, phase 1/2 study in up to 18 participants (including at least 3 adolescents between 12 and 17 years of age, inclusive) with β-thalassemia major. the study will evaluate the safety and efficacy of autologous hematopoietic stem cell transplantation (hsct) using lentiglobin bb305 drug product \[autologous cd34+ hematopoietic stem cells transduced with lentiglobin bb305 lentiviral vector encoding the human βa-t87q-globin gene\].

subject participation for this study will be 2 years. subjects who enroll in this study will be asked to participate in a subsequent long-term follow up study that will monitor the safety and efficacy of the treatment they receive for up to 13 years post-transplant.

Eligibility criteria:
inclusion criteria: * participants between 12 and 35 years of age, inclusive, at the time of consent/assent, and able to provide written consent/assent, if applicable. * diagnosis of β-thalassemia major and a history of at least 100 ml/kg/year of prbcs or ≥8 transfusions of prbcs per year for the prior 2 years. * eligible for allogeneic bone marrow transplant. * treated and followed for at least the past 2 years in a specialized center that maintained detailed medical records, including transfusion history. exclusion criteria: * positive for presence of human immunodeficiency virus type 1 or 2 (hiv 1 and hiv 2). * a white blood cell (wbc) count \<3 × 10\^9/l, and / or platelet count \<100 × 10\^9/l if not due to hypersplenism. * uncorrected bleeding disorder. * any prior or current malignancy or myeloproliferative or immunodeficiency disorder. * immediate family member with a known or suspected familial cancer syndrome (including but not limited to hereditary breast and ovarian cancer syndrome, hereditary non-polyposis colorectal cancer syndrome and familial adenomatous polyposis). * receipt of an allogeneic transplant. * advanced liver disease, including persistent aspartate transaminase (ast), alanine transaminase (alt), or total bilirubin value \>3 × the upper limit of normal, liver biopsy demonstrating cirrhosis, extensive bridging fibrosis, or active hepatitis. * kidney disease with a calculated creatinine clearance \<30% normal value. * uncontrolled seizure disorder. * diffusion capacity of carbon monoxide (dlco) \<50% of predicted (corrected for hemoglobin). * a cardiac t2\* \<10 ms by magnetic resonance imaging (mri). * any other evidence of severe iron overload that, in the investigator's opinion, warrants exclusion. * clinically significant pulmonary hypertension, as defined by the requirement for ongoing pharmacologic treatment or the consistent or intermittent use of supplemental home oxygen. * participation in another clinical study with an investigational drug within 30 days of screening. * any prior or current malignancy or myeloproliferative disorder. * prior receipt of gene therapy.

Keywords: gene therapy β thalassemia hemoglobin anemia cd34
to study the characteristics of different types of vertigo in patients attending the ear nose & throat (ent) clinics.

Conditions: Vertigo

Summary: the vertigo study is likely to help determine characteristics of different types of vertigo in patients presenting in the ear nose \& throat (ent) clinics with complaints of dizziness. moreover, it will also help to develop an understanding about the current management practices of this condition at local level.


Eligibility criteria:
inclusion criteria: * male or female patients 18 years of age and older * patients with vestibular vertigo of known or unknown origin * patients who are willing and able to provide written informed consent exclusion criteria: * patients with any condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion based on clinical judgment * patient with psychiatric disorders, significant neurological disorder or spinal cord damage that would make the evaluation difficult for the investigator * patients who are not willing to give informed consent * patients with a known history of hypersensitivity to betahistine * patients with a history of pheochromocytoma

Keywords: vertigo, dizziness
the research of standard diagnosis and treatment for severe hsp in children

Conditions: Henoch-Schoenlein Purpura

Summary: this study is performed to evaluate the efficacy and safety of various measures in the treatment of severe hsp in children.

henoch-schonlein purpura (hsp) is a systemic vasculitis affecting small vessels with immunoglobulin a (iga)-dominant immune deposits. the clinical manifestations of severe hsp vary from massive hemorrhage and necrosis of the skin to severe gastrointestinal symptoms. the course of the disease would encounter delay and relapse. to some extent, the traditional therapy alleviate the clinical symptoms, but fail to timely clear up the immune depositions, causing the damage to the kidney. in the study, the patients will be given dexamethasone 0.5mg/kg/d, then be randomised to receive either gamma globulin i.v. or hemoperfusion if the disease can't be controlled with steroid treatment for more than two days. the investigators will explore the biological markers and compare the efficacy and safety of both measures in the treatment of serve hsp in children. the purpose of the study is to optimize the treatment of severe hsp for children with different ages.

Eligibility criteria:
inclusion criteria: * severe hsp: could not be controlled with dexamethasone 0.5mg/kg/d or the total dose above 20mg/d for more than two days exclusion criteria: * the children with congenital diseases
the effect of music listening on nursing students

Conditions: Stress; Physiological Stress

Summary: the purpose of this study is to explore the effect of sedative and stimulative music listening on physiological responses among nursing students.


Eligibility criteria:
inclusion criteria: * a senior, junior, or second-semester sophomore in the traditional undergraduate bachelor of science in nursing (bsn) program * a student in the accelerated bsn program exclusion criteria: •self-reported hearing impairments.

Keywords: heart rate skin conductance music
the effect of rtms treatment on alzheimer's and sleep quality

Conditions: Alzheimer's Disease

Summary: this research is being conducted to study whether rtms (repetitive transcranial magnetic stimulation) could be potentially used as a treatment for alzheimer's disease. rtms is a technique that stimulates the brain by rapidly switching a magnetic field in a coil placed over your head. prior to rtms, single pulse tms will be used to localize the specific brain region that we are interested in.

upon meeting the inclusion criteria and providing informed consent, each participant will complete a series of cognitive assessments and rtms treatments at the tms lab at riverview health center. each treatment session will involve implementing rtms, while the patient is involved in a cognitive exercise such as naming object or action. the study sessions will be scheduled as follows: block 1: 5 days/week for two weeks followed by 2 days a week for 1 week, followed by once a week for 1 week (total of 13 treatments); pause: 4 weeks of no treatment; and block 2: another 13 sessions of treatment with the same pattern as block 1. one of these two sets of treatment (block 1 or block 2) will be sham and one will be real. sham treatment sessions are identical to real treatment sessions, except that there is no magnetic stimulation. patients will be randomly assigned to receive either sham or real treatment first. the purpose of sham treatment is to have a control group data that the plausible improvement as a result of rtms can be compared to. by designing two sets of sham-real or real-sham treatment sessions, every participant will receive a real treatment, while we will also have control data. the cognitive assessments will be done at the baseline, and then on weekly basis. a subgroup of the study population will be recruited for investigating the second objective: effect of rtms on sleep quality. those patients will be required to sign a second consent; then, the patients will go through full-night sleep study at misericordia health center at the same time intervals as their cognitive assessments.

Eligibility criteria:
inclusion criteria: * individuals must have a moca score between 5 and 26, indicating mild cognitive impairment or dementia. * participants must have probable early or moderate alzheimer's disease as confirmed by their treating neurologist or psychiatrist, and/or by the co-investigators. exclusion criteria: * a recent (the last 3 months) history of stroke, recent (the last 3 months) head injury and loss of consciousness, any history of epilepsy, seizures, multiple sclerosis (ms), amyotrophic lateral sclerosis (als), or autism. * recent changes in medication (i.e. patients should be in a relatively stable phase of disease). * the presence of metallic objects in the body; dental implants are fine but people with pacemakers are to be excluded; basically anything that is unsafe under mri would be considered unsafe for tms application.

Keywords: alzheimer's rtms sleep quality dementia memory
can fatigability neuromuscular explain chronic fatigue in people with multiple sclerosis?

Conditions: Sclerosis, Multiple

Summary: chronic fatigue is the most common and debilitating symptom in multiple sclerosis patients. this chronic fatigue affects their quality of life by decreasing their capacity to perform simple tasks of daily life. the aim of the present project is to determine whether deteriorated neuromuscular function (i.e. increased fatigability) is involved in this feeling of chronic fatigue. because the causes of this feeling are multi-dimensional, a large battery of tests will allow us to better understand the origin of chronic fatigue. a better knowledge of chronic fatigue etiology will allow to optimize rehabilitation treatments to decrease the apparition/persistence of chronic fatigue and in fine improve quality of life.


Eligibility criteria:
inclusion criteria: for patients: * aged ≥ 18 and ≤ 70 years * men or women * with multiple sclerosis since 2 and 25 years * affiliates or beneficiaries of social security scheme * signed consent for healthy volunteers: * aged ≥ 18 and ≤ 70 years * men or women * matched in accordance with age, sex and level of physical activity exclusion criteria: for patients and healthy volunteers: * high heart rate resting * blood pressure \> 144/94 mmhg * recent adjustment of drug or drug can have an impact on fatigue or stimulant for fatigue * taking neuroactive substances that can alter corticospinal excitability * contraindication at application magnetic field * contraindication at magnetic resonance imaging (mri) * currently participating in a structured exercise program * pregnant for patients only: * spasticity or cerebellar ataxia * abnormal range of motion (toe and/or ankle) * musculoskeletal injuries that impedes pedaling * appearance of symptoms of multiple sclerosis in the 90 days preceding the study for healthy volunteers: - neurological diseases, cardiovascular, musculoskeletal

Keywords: sleep assessment neuromuscular fatigability multiple sclerosis chronic fatigue
comparison of bnp and nt-probnp in the management of patients with chronic and acute heart failure

Conditions: Heart Failure

Summary: the purpose of this study is to compare the changes in b-type natriuretic peptide (bnp) and amino-terminal fragment of probnp (nt-probnp) in outpatients managed in the heart failure (hf) clinic initiated on the angiotensin receptor neprilysin inhibitor (entresto) and directly compare the prognostic values of bnp and nt-probnp in patients admitted with acute decompensated hf.

both natriuretic peptides (np), namely b-type np (bnp) and amino-terminal fragment of probnp (nt-probnp), have an established role in the management of patients with heart failure (hf).\[1\] however, the clinical utility of bnp has recently been questioned with the paradigm-hf trial, which demonstrated increased bnp and reduced nt-probnp levels following the administration of entresto, a newly approved angiotensin receptor neprilysin inhibitor (arni).\[2.3\] the increase in bnp was thought to be reflective of reduced metabolism of bnp as a result of neprilysin inhibition.\[2\] however, this claim was based on observations of three points in time and with wide confidence intervals.\[3\] in addition, there has been no attempt to demonstrate dose relationships. furthermore, although both bnp and nt-probnp have each been shown to predict hf readmission in hospitalized patients \[1,4,5\] the relative utility between the two nps for this prediction remains unclear. we therefore hypothesize that once beyond the initiation of arni therapy, bnp and nt-probnp will be equally predictive of clinical events in patients with hf. the studies comprise of two separate protocols: a. outpatient protocol - the effect of entresto measuring the changes in the nt-probnp and bnp test results. this protocol will be conducted on ambulatory outpatients initiating on entresto. patients will have blood sampling for the measurements of bnp and nt-probnp at baseline, at the first and second up titration in dose of entresto, and at 6 months and 1st year after starting entresto. b. inpatient protocol-predicting outcomes. this will be conducted on patients admitted for acute decompensated hf. blood sampling for bnp and nt-probnp will be collected in different time points (admission, hospital discharge, 30th day, 90th day, and 180th day) and measure its changes.

Eligibility criteria:
inclusion criteria: out patient protocol - patients with chronic heart failure being followed in the heart failure clinic eligible to switch angiotensin converting enzyme inhibitors (acei) or angiotensin receptor blockers (arb) to arni (entresto). in patient protocol - patients admitted due to acute decompensated heart failure

Keywords: bnp nt-probnp arni sacubitril/valsartan
post-marketing surveillance of ventilat® metered dose inhaler in chronic obstructive bronchitis

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: study to obtain further information on the tolerability and efficacy of ventilat® metered-dose inhaler in the treatment of chronic obstructive bronchitis under conditions of daily practice


Eligibility criteria:
inclusion criteria: * primarily patients of both genders older than 40 years, who suffer from chronic obstructive bronchitis * only patients who have not been treated with an anticholinergic within the last year are to be considered for inclusion exclusion criteria: •contraindications listed in the instructions for use/summary of product characteristics for ventilat® metered dose inhaler
violet light for the suppression of myopia

Conditions: Myopia; Phototherapy

Summary: the study explores the suppression of myopia via violet light.

the study uses violet light-emitting lamps as the variable and regular, white light lamps as the control in assessing whether violet light, especially during over periods of dawn and dusk could help suppress the progression of myopia in developing children.

Eligibility criteria:
inclusion criteria: * children must be between 5 to \<13 years old. * diagnosis of myopia (icd-10-cm diagnosis code h52.13) with refractive error: 1. myopia -1.00d to -6.00d spherical equivalent (se) in both eyes 2. astigmatism \<=1.50d in both eyes 3. anisometropia \<=1.00d se • relocation outside of the cchmc area within the next 12 months is not anticipated. exclusion criteria: current or previous myopia treatment with atropine, pirenzepine, or other antimuscarinic agents * current or previous use of bifocals, progressive addition lenses, or multi-focal contact lenses * current or previous use of orthok, rigid gas permeable, or other contact lenses being used to reduce myopia progression * current or prior history of manifest strabismus, amblyopia, or nystagmus * abnormality of cornea, lens, central retina, iris, or ciliary body * prior eyelid, strabismus, intraocular, or refractive surgery * down syndrome or cerebral palsy

Keywords: myopia violet light
sleep quality of physiotherapy students quality of life and physical activity level

Conditions: Sleep Quality; Quality of Life; Physical Activity

Summary: there is a high prevalence of poor sleep quality among university students studying in different areas such as medicine, nursing, art, science, social work etc. and in different countries. however, the studies done especially for physiotherapy students, and in turkey, as well, are not many. therefore, we aimed to search the sleep quality among physiotherapy students, and observe the association between the health related quality of life and physical activity level of the physiotherapy students. the physiotherapy students were included. their quality of sleep will be assessed by pittsburgh sleep quality index. the physical activity will be searched by international physical activity questionnaire, and sf-36 will be used to assess quality of life. data is going to analyzed statistically

therefore, recent studies are focusing on the sleep quality of university students in different countries, and reporting that medical students pharmacy students, nursing students are experiencing poor quality of sleep. however, to our knowledge, studies done on sleep quality of students and especially the physiotherapy students are not available in turkey, yet. hence, since the university students are one of the high risk groups for developing poor sleep quality, we aimed to evaluate if the sleep quality of the physiotherapy students in both gender are associated with their quality of life and physical activity level.

Eligibility criteria:
inclusion criteria: * being physiotherapy and rehabilitation students * being the age between 18-26 years old * being voluntary to participate to the study exclusion criteria: * not having any systemic disease * any expressed psychological condition

Keywords: sleep quality body mass index active life academic performance
efficacy of tart cherry juice to reduce pain and inflammation among patients with inflammatory osteoarthritis

Conditions: Pain; Inflammation

Summary: the purpose of this study is to assess the effects of tart cherry juice to reduce pain and inflammation among individuals with arthritis.

numerous antioxidant and anti-inflammatory agents have been identified in tart cherries, and a study among healthy, non-exercising individuals demonstrated that cherry consumption decreased serum inflammatory biomarkers after 14 days. osteoarthritis (oa) is a common syndrome affecting 65 million americans characterized by pain, inflammation, and disability. such natural anti-inflammatory effects of cherry consumption may be beneficial for the management and treatment of osteoarthritis and inflammatory diseases. the purpose of this randomized, double-blind, placebo controlled study is to examine individuals with inflammatory oa and assess the analgesic and anti-inflammatory effects of tart cherry juice as compared to a placebo drink among twenty 30-70 y/o oa subjects.

Eligibility criteria:
inclusion criteria: * diagnosed with inflammatory osteoarthritis * in good general health * stable pattern of anti-inflammatory or pain relieving drug use for 3 months prior to study * ability and willingness to maintain consistent pattern of anti-inflammatory or pain relieving drug use during the course of the study, and to not seek any other treatment during the study * ability and willingness to consume juice or placebo drink for 21 consecutive days, and to participate in screening measures, including a blood draw, before and after the intervention period exclusion criteria: * pregnancy * serious medical conditions such as recent heart attack or stroke, cancer, diabetes (type 1 and type 2), or gastrointestinal ulcers * individuals who have not been on a stable dose of pain medications or pain modalities for at least 3 months, including muscle relaxants, tender point anesthetic injections, systemic or intrabursal or intraarticular steroids, or any investigational drug/device in the prior 90 days * individuals who have used nonpharmacologic pain therapies including acupuncture, ultrasound, or transcutaneous electrical nerve stimulation within the past 30 days

Keywords: pain inflammation osteoarthritis
cannabis effects as a function of sex

Conditions: Pain; Abuse, Drug

Summary: the purpose of this research is to assess the impact of cannabis on the analgesic and abuse-related effects between men and women

the proposed study will compare smoked cannabis's dose-dependent, analgesic and abuse-related effects between men and women and variables that underlie these sex-dependent differences, including pharmacokinetics of thc.

Eligibility criteria:
inclusion criteria: * male or non-pregnant female aged 21-55 years * report use of cannabis an average of 1-7 days per week * not currently seeking treatment for their cannabis use * urine test positive for recent cannabis use for heavy users * no reported adverse effects with cannabis smoking in light users * have a body mass index from 18.5 - 34kg/m2. * able to perform all study procedures * females: currently practicing a non-hormonal effective form of birth control * females: must be regularly cycling exclusion criteria: * meeting dsm-v criteria for any substance use disorder other than nicotine, caffeine, or cannabis use disorder * report using other illicit drugs in the prior 4 weeks * history or current evidence of severe psychiatric illness or medical condition judged by the study physician and pi to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent. * current use of medical cannabis, prescription analgesics, or any medications that may affect study outcomes * current pain * insensitivity to the cold water stimulus of the cold pressor test * females: using a hormonal contraceptive

Keywords: pain cannabis thc